Clinical Research — Updated June 2026

Psilocybin for Depression — What the Science Actually Shows

✅ Breakthrough Therapy × 2 🔬 Phase 3 Trials Active 52% FDA Approval by 2028 🌏 Available in AU, OR, CO Now

Psilocybin is showing some of the most striking antidepressant results ever recorded in clinical trials — 71% response rates in MDD, 29% remission from a single dose in treatment-resistant depression. Here's everything known about the evidence, and daily AI predictions on when it becomes legally available as a treatment.

280M
People with depression worldwide
30%
Have treatment-resistant depression (TRD)
71%
Response rate in Hopkins MDD Phase 2
52%
Oracle probability: FDA approval by 2028

The Clinical Evidence: What Trials Actually Show

COMPASS Pathways — Phase 2b (2022)

COMP360 25mg: Treatment-Resistant Depression

29%
Remission rate at 3 weeks (vs. 8% placebo)

n=233, randomized, double-blind. Single psilocybin session. The most rigorous TRD trial to date. Dose-dependent response: 25mg superior to 10mg and 1mg. Led directly to Phase 3 initiation.

Johns Hopkins — Phase 2 (Davis et al., 2021)

Major Depressive Disorder: 2-Session Protocol

71%
Response rate at 4 weeks (54% remission)

n=24, randomized waitlist-controlled. Two psilocybin sessions + supportive psychotherapy. HAMD-17 scores reduced by 54%. Effects maintained at 3-month follow-up in majority of responders.

Imperial College London (Carhart-Harris 2021)

Psilocybin vs. Escitalopram (SSRI): Head-to-Head

Both worked
Psilocybin superior on secondary measures

n=59 MDD patients, 6 weeks. Primary QIDS endpoint not statistically significant. BUT psilocybin showed significantly greater improvements in emotional processing, wellbeing, suicidal ideation. Faster onset.

Usona Institute — Phase 2 (PSILY trial)

Synthetic Psilocybin for MDD

Positive
Phase 2 complete, Phase 3 initiated

Single-dose synthetic psilocybin (mescaline-free, pharmaceutical grade). 49% met response criteria at Day 43. Usona's NDA pathway targets MDD (vs. COMPASS targeting TRD). Phase 3 ongoing.

NYU Langone — Phase 2 (2020)

Psilocybin for Alcohol Use Disorder + Depression

83%
Response rate for comorbid AUD+depression

n=24 with alcohol use disorder, many with comorbid depression. 83% achieved abstinence after 2 sessions. Depression remission rates exceptional. Supporting evidence for broader mental health applications.

COMPASS Phase 3 — ONGOING (NCT05548439)

COMP360 Phase 3: TRD (The Pivotal Trial)

~2026-27
Estimated data readout

Multi-site Phase 3, ~900 participants, treatment-resistant MDD. This is the trial that determines FDA approval. If positive, NDA filing expected 2027-2028. Oracle monitors this daily for enrollment, adverse event, and regulatory signals.

How Psilocybin Works Against Depression

The mechanism is fundamentally different from SSRIs — which is why it can help people for whom SSRIs fail.

1

5-HT2A Receptor Activation → Neuroplasticity Burst

Psilocin (active metabolite) binds to serotonin 5-HT2A receptors with high affinity. This triggers a cascade of BDNF (brain-derived neurotrophic factor) release — the same "growth factor" targeted by antidepressants but through a more direct, more powerful pathway. New synaptic connections form within hours. In depressed brains, years of negative-state narrowing of neural pathways can be partially reversed.

2

Default Mode Network (DMN) Suppression

Depression is strongly correlated with hyperactivity in the Default Mode Network — the brain network involved in self-referential rumination ("I am worthless", "nothing will ever change"). Psilocybin dramatically and rapidly suppresses DMN activity in fMRI studies. This creates the subjective sense of "ego dissolution" at high doses — but at therapeutic doses, it primarily reduces the relentless self-critical internal loop that characterizes depression.

3

Psychedelic State = Therapeutic Window

The psilocybin experience itself — guided by therapists — creates a state of heightened neuroplasticity and emotional openness where psychological insights become possible that are unavailable in normal consciousness. Patients frequently describe accessing suppressed memories, reprocessing traumatic events, and experiencing profound perspective shifts. The psychological experience appears to be therapeutically active — not just a side effect. This is why psilocybin therapy always pairs drug with therapy.

4

Lasting Structural Changes

Post-session neuroimaging shows measurable increases in dendritic spine density and new synaptic connections that persist weeks after the drug has cleared (psilocybin's half-life is ~3 hours). This structural remodeling may explain why a single session can produce antidepressant effects lasting 6-12 months. SSRIs require daily dosing because they don't create this structural change — they only maintain elevated serotonin levels.

Psilocybin vs. Traditional Antidepressants

Factor Psilocybin Therapy SSRIs (e.g., Lexapro) SNRIs (e.g., Effexor)
Onset of effect Days (acute) to 2-4 weeks 4-6 weeks 4-8 weeks
Dosing frequency 1-3 sessions total Daily, indefinitely Daily, indefinitely
Duration of remission 6-12+ months per session While taking medication While taking medication
TRD response rate 29-71% (across trials) ~15% for 3rd+ antidepressant ~15% for 3rd+ antidepressant
Sexual side effects Very rare, temporary 40-80% affected 30-60% affected
Weight effects Minimal Weight gain common Variable
Withdrawal risk None (non-addictive) Discontinuation syndrome Significant withdrawal
FDA approval status Phase 3 trials (TRD) Approved Approved
Insurance coverage Not yet (OR/CO: out of pocket) Yes Yes
Cost per year $3,000-6,000 (1-2 sessions) $50-200/year (generic) $100-1,200/year

Active Clinical Trials for Psilocybin + Depression (2026)

COMP360 Phase 3 — Treatment-Resistant MDD

Phase 3 — Pivotal

NCT05548439 · ~900 participants · Multi-site USA/EU. The trial that determines FDA approval. Seeking participants who failed ≥2 antidepressants. Still enrolling in select sites.

PSILY-2 Phase 3 — Major Depressive Disorder

Phase 3

Synthetic psilocybin for MDD (broader population than COMPASS TRD target). Non-profit, no commercial conflict. Targets non-treatment-resistant MDD. Strong Phase 2 data.

Psilocybin for MDD + Alcohol Use Disorder

Phase 2

Dual-diagnosis population. 2-session protocol with certified therapist support. Prior Phase 2 showed exceptional results. Ongoing expansion of the evidence base. Contact: psychedelics.jhu.edu

Psilocybin for Late-Life Depression

Phase 2

Targeting elderly depression (60+) — a population severely underserved by current antidepressants. First major trial specifically for geriatric depression. Novel population with high medical need.

Psilocybin for Cancer-Related Depression

Phase 2

Building on Carhart-Harris lab's extensive work. Targeting existential depression in terminal cancer patients — a population where quality of life impact is measurable. Strong prior case evidence.

Low-Dose Psilocybin for MDD

Phase 2

Investigating whether sub-full-dose (15mg vs 25mg) produces equivalent antidepressant effects with reduced adverse events. Important for developing outpatient/less intensive treatment models if approved.

FDA Approval Timeline: Where Are We Now?

2018
FDA Grants Breakthrough Therapy Designation — COMPASS (TRD)
First psychedelic compound to receive Breakthrough Therapy. Designation means FDA provides intensive guidance and faster review. Confirms FDA view that COMP360 "may demonstrate substantial improvement" over existing TRD treatments.
2019
FDA Grants Breakthrough Therapy Designation — Usona (MDD)
Second psychedelic Breakthrough designation. Two separate drugs targeting different depression populations — validating the evidence base across the field, not just one company.
2022
COMPASS Phase 2b Published — NEJM
Landmark Phase 2b results published in New England Journal of Medicine. 29% remission from single 25mg session in TRD. Phase 3 initiated. Considered the pivotal moment in psilocybin depression research credibility.
2023
Australia Becomes First Country to Approve Psilocybin for TRD
TGA (Australia's FDA) approves psilocybin for treatment-resistant depression, effective July 1 2023. Authorized psychiatrists can prescribe to TRD patients. First regulatory approval in the world. Creates international precedent.
2024–2026
COMPASS + Usona Phase 3 Trials Actively Enrolling
Both pivotal trials in progress. ~900+ participants being recruited across US and international sites. Data readouts expected 2026-2027 for COMPASS, 2027-2028 for Usona.
2027–2028
Expected NDA Submission (if Phase 3 Positive)
OOTWOracle's 8-agent system assigns 52% probability to FDA approval by January 2028. The key risk factors: Phase 3 may show smaller effects than Phase 2, REMS requirements may limit access, or political headwinds could slow DEA scheduling review. A positive Phase 3 still requires ~12 months FDA review.
⚠️ How to Access Psilocybin for Depression Right Now (June 2026)

Oregon: Licensed service centers operational statewide. No prescription needed. ~$1,500-3,000 per session. Not covered by insurance yet.
Colorado: Healing centers licensed under Prop 122. Adult possession and gifting legal. Similar cost structure.
Australia: Authorized psychiatrists can prescribe psilocybin for TRD. Only option with medical oversight and insurance pathway.
Clinical Trials: Free or reduced-cost access. Visit clinicaltrials.gov and search "psilocybin depression" for open studies.

OOTWOracle Predictions: Psilocybin Depression Treatment Timeline

FDA approves psilocybin for TRD (COMP360)
52%
by Jan 2028
COMPASS Phase 3 data: positive result
61%
by Jan 2027
Usona FDA approval for MDD
44%
by Jan 2029
Major US insurer covers psilocybin therapy
67%
within 2yr of FDA approval
10th country approves psilocybin for depression
58%
by Jan 2028
VA system initiates psilocybin for veteran depression
39%
by Jan 2028

Oracle Agent Perspectives on Psilocybin for Depression

🏛️ FDA Regulatory Reviewer
The COMPASS Phase 2b data is genuinely compelling — 29% remission from a single session in TRD is clinically meaningful. The REMS program design is straightforward (in-facility administration, therapist certification). The question is whether Phase 3 replicates Phase 2 in a larger, more heterogeneous population. FDA will require robust safety data given the drug's subjective experience intensity.
🔬 MAPS Researcher
The neuroplasticity mechanism is not a hypothesis anymore — it's documented in multiple independent labs using multiple imaging modalities. What's remarkable is that psilocybin doesn't just mask depression symptoms like SSRIs do. It appears to structurally change the depressed brain. We may be looking at the first true disease-modifying intervention in psychiatry.
💊 Neuropharmacologist
The Carhart-Harris vs. escitalopram trial result is probably the most important data point for the depression field. Not because psilocybin clearly "won" on the primary endpoint — but because it performed equivalently while working completely differently, faster, with fewer side effects, and with patients preferring it. That combination means even a modest Phase 3 result is likely sufficient for approval given medical need.
💰 Biotech Investor
The TRD market alone is $8B+ annually with terrible outcomes. Psilocybin that can produce 6-month remission from 1-3 sessions is not competing with SSRIs — it's complementary, for the 84 million people SSRIs failed. COMPASS at $1B market cap is undervalued if Phase 3 succeeds. The insurance reimbursement unlock (following Spravato precedent) is when this becomes a massive market.

Frequently Asked Questions

Does psilocybin work for depression? +
Yes, based on clinical evidence. Phase 2 trials show 29-71% response rates depending on the population, dose, and protocol. The strongest evidence is for treatment-resistant depression (TRD) — patients who've failed ≥2 antidepressants. FDA has granted Breakthrough Therapy status based on this evidence. Phase 3 trials are ongoing to confirm efficacy at scale.
How many sessions of psilocybin therapy does it take? +
Most clinical protocols use 1-3 sessions. COMPASS trials use a single 25mg session. Johns Hopkins protocols typically use 2 sessions (approximately 2 weeks apart), each preceded and followed by therapist preparation/integration sessions. Oregon service centers typically offer single or multi-session protocols. The key is therapist-supported preparation and integration — the drug session alone is not the complete treatment.
Is psilocybin safe for people with depression? +
Clinical trials have shown a favorable safety profile with proper screening and clinical support. Psilocybin has very low physiological toxicity and no documented lethal dose in humans. Psychological risks include acute anxiety, confusion, or disturbing experiences during the session — which is why therapist support is critical. Contraindications include personal or family history of psychosis or bipolar I disorder. It should not be combined with SSRIs/MAOIs without medical guidance. The risks are real but manageable in clinical settings.
Why isn't psilocybin FDA-approved yet if it works? +
The FDA approval process requires Phase 3 trials — large, randomized studies of 900+ patients across multiple sites. This takes years and hundreds of millions of dollars. COMPASS and Usona are in Phase 3 now (started 2023-2024). The process is working as designed — it just takes time. Phase 2 data are compelling but not sufficient for approval. FDA also needs to design the REMS program, which takes additional time.
Can I combine psilocybin therapy with my antidepressant? +
This is an important clinical question. SSRIs may blunt psilocybin's effects by downregulating 5-HT2A receptors. Many clinical protocols require tapering off SSRIs 2-4 weeks before psilocybin therapy. MAOIs combined with psilocybin can cause serotonin syndrome (dangerous). Do NOT make medication changes without physician guidance. Oregon service facilitators are not physicians and cannot advise on this — seek consultation with a psychiatrist familiar with psychedelic medicine before any session.
How long do psilocybin's antidepressant effects last? +
Most clinical trials show sustained effects for at least 3-6 months, with many studies showing effects at 12 months in a significant proportion of responders. The Hopkins trial showed 71% maintained response at 3 months; roughly 54% maintained remission. Some patients report multi-year relief from a single course. Effects appear dose-dependent — the 25mg dose in COMPASS Phase 2 showed superior sustained effects to lower doses. Repeat sessions appear to extend the benefit period.

🔮 Track Psilocybin Approval Progress Daily

OOTWOracle's 8-agent AI system monitors FDA signals, COMPASS trial updates, congressional bills, and international precedents — updating probability scores every 24 hours. Be first to know when psilocybin therapy gets one step closer to legal availability.

View Today's Oracle Report →

Related Research

🍄 Psilocybin FDA Approval Tracker

COMPASS, Usona NDA timelines + daily AI confidence scores

🔬 Clinical Trials 2026 — How to Enroll

Active trials, eligibility criteria, how to apply

🌏 Australia TGA Approval — World First

How Australia approved psilocybin for TRD and what comes next

🗺️ Psilocybin Legal States 2026

Oregon, Colorado, California — where you can access legally now

💉 Ketamine Therapy Regulation 2026

The approved comparison: Schedule III, FDA-approved, insurance covered

🍄 Is Microdosing Legal? 2026

Federal law, state laws, decriminalized cities guide